Cost-Effectiveness Evaluation of Oral CGRP Antagonists, Atogepant and Rimegepant, for the Preventative Treatment of Episodic Migraine: Results from a US Societal Perspective Model

被引：0
|
作者：
Ryan Thaliffdeen
Anthony Yu
Karen Rascati
机构：
[1] The University of Texas at Austin,Health Outcomes Division, College of Pharmacy
来源：
Clinical Drug Investigation | 2024年 / 44卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：209 / 217
页数：8
相关论文
共 50 条
  • [1] Cost-Effectiveness Evaluation of Oral CGRP Antagonists, Atogepant and Rimegepant, for the Preventative Treatment of Episodic Migraine: Results from a US Societal Perspective Model
    Thaliffdeen, Ryan
    Yu, Anthony
    Rascati, Karen
    CLINICAL DRUG INVESTIGATION, 2024, 44 (03) : 209 - 217
  • [2] Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: Results from the US societal and payer perspectives
    Sussman, Matthew
    Benner, Jennifer
    Neumann, Peter
    Menzin, Joseph
    CEPHALALGIA, 2018, 38 (10) : 1644 - 1657
  • [3] Cost-effectiveness of migraine prevention: Results from a model of topiramate treatment
    Brown, JS
    Papadopoulos, G
    Neumann, PJ
    Friedman, M
    Menzin, J
    VALUE IN HEALTH, 2004, 7 (03) : 237 - 237
  • [4] Cost-effectiveness of rimegepant oral lyophilisate compared to best supportive care for the acute treatment of migraine in the UK
    Johnston, K.
    Powell, L.
    Popoff, E.
    L'Italien, G.
    Pawinski, R.
    Ahern, A.
    Large, S.
    Tran, T.
    Jenkins, A.
    JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [5] Cost-effectiveness of rimegepant oral lyophilisate compared to best supportive care for the acute treatment of migraine in the UK
    Johnston, Karissa
    Powell, Lauren C.
    Popoff, Evan
    L'Italien, Gil J.
    Pawinski, Robert
    Ahern, Aideen
    Large, Sam
    Tran, Thang
    Jenkins, Aaron
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 627 - 643
  • [6] Cost-effectiveness of topiramate in migraine prevention: Results from a pharmacoeconomic model of topiramate treatment
    Brown, JS
    Papadopoulos, G
    Neumann, PJ
    Friedman, M
    Miller, JD
    Menzin, J
    HEADACHE, 2005, 45 (08): : 1012 - 1022
  • [7] COST-EFFECTIVENESS OF FREMANEZUMAB FOR THE TREATMENT OF MIGRAINE IN ENGLAND FROM A HEALTHCARE SYSTEM PERSPECTIVE
    Skroumpelos, A.
    Freddi, M.
    Akcicek, H.
    Cohen, J. M.
    Driessen, M. T.
    VALUE IN HEALTH, 2021, 24 : S160 - S160
  • [8] Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score ® Test from a US Societal Perspective
    Berdunov, Vladislav
    Carter, Gebra Cuyun
    Laws, Ewan
    Luo, Roger
    Russell, Christy A.
    Campbell, Sara
    Abdou, Yara
    Force, Jeremy
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2024, 16 : 471 - 482
  • [9] COST-EFFECTIVENESS OF TREATMENT WITH TRASTUZUMAB IN PATIENTS WITH EARLY BREAST CANCER FROM THE PORTUGUESE SOCIETAL PERSPECTIVE
    Macedo, A.
    Monteiro, I
    Ray, J. A.
    Cirrincione, A.
    Andrade, S.
    Pereira, C.
    VALUE IN HEALTH, 2008, 11 (06) : A472 - A472
  • [10] The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspective
    van Asten, Freekje
    Michels, Charlotte T. J.
    Hoyng, Carel B.
    van der Wilt, Gert Jan
    Klevering, B. Jeroen
    Rovers, Maroeska M.
    Grutters, Janneke P. C.
    PLOS ONE, 2018, 13 (05):
12345